Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

In a phase 3 clinical trial involving previously treated patients with advanced renal-cell carcinoma, progression-free survival was significantly longer with the VEGF receptor inhibitor cabozantinib than with everolimus (7.4 months vs. 3.8 months). Renal-cell carcinoma is the most common form of kid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2015-11, Vol.373 (19), p.1814-1823
Hauptverfasser:	Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anilides - adverse effects Anilides - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Axl protein c-Met protein Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Chemotherapy Disease-Free Survival Drug development Drug resistance Enzyme inhibitors Everolimus Female Humans Inhibitor drugs Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Male Medical prognosis Metastases Metastasis Middle Aged Patients Protein-tyrosine kinase Pyridines - adverse effects Pyridines - therapeutic use Quality of Life Renal cell carcinoma Sirolimus - adverse effects Sirolimus - analogs & derivatives Sirolimus - therapeutic use Survival Analysis Targeted cancer therapy Tumors Vascular endothelial growth factor Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!